4172.TWO InnoPharmax Inc.
- Market cap
- TWD 1.08B
- P/E
- -
- P/B
- 2.14x
- ROE
- -44.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 4172.TWO undervalued?
Graham numberThe Graham number of InnoPharmax Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
InnoPharmax Inc. fundamental analysis
No fundamental analysis for InnoPharmax Inc. yet.
InnoPharmax Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About InnoPharmax Inc.
InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. The company offers Imipenem and Cilastatin sodium solution under the Bestnem brand for the treatment of infections caused by susceptible organisms, such as lower respiratory tract, skin and skin structure, intra-abdominal, gynecologic, bone, and joint infections; contrast agents, such as gadopentetate dimeglumine under the …
Full company profileInnoPharmax Inc. financial statements
InnoPharmax Inc. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 84.9M | 137M | 48.1M | 29.1M | 46.1M | 32.3M | 69.0M |
| Gross Profit | 34.1M | 58.1M | 7.41M | -377K | 17.5M | 20.8M | 9.83M |
| Operating Income | -74.9M | -30.3M | -74.4M | -93.3M | -64.8M | -96.0M | -172M |
| EBITDA | -74.5M | -18.8M | -69.8M | -88.7M | -53.9M | -90.0M | -174M |
| Net Income | -87.9M | -43.9M | -93.0M | -103M | -70.8M | -99.3M | -184M |
| EPS | -1.22 | -0.57 | -1.06 | -1.19 | -0.76 | -1.02 | -1.70 |
| Balance Sheet | |||||||
| Total Assets | 597M | 680M | 556M | 489M | 524M | 633M | 469M |
| Total Liabilities | 81.4M | 209M | 24.6M | 58.3M | 48.6M | 30.2M | 49.8M |
| Shareholders' Equity | 515M | 472M | 532M | 431M | 476M | 603M | 419M |
| Cash & Short-term Investments | 168M | 242M | 187M | 105M | 152M | 294M | 97.3M |
| Total Debt | 33.7M | 29.9M | 5.57M | 37.6M | 21.5M | 15.4M | - |
| Cash Flow | |||||||
| Operating Cash Flow | -42.5M | -47.4M | -50.0M | -100M | -48.6M | -76.2M | -134M |
| Capital Expenditure | 0.00 | 1.86M | 1.45M | 128K | 397K | 589K | 276K |
| Free Cash Flow | -42.5M | -49.2M | -51.5M | -100M | -49.0M | -76.8M | -134M |
| Ratios | |||||||
| ROE | -17.1% | -9.3% | -17.5% | -23.9% | -14.9% | -16.5% | -44.0% |
| ROA | -14.7% | -6.5% | -16.7% | -21.1% | -13.5% | -15.7% | -39.3% |
| Net Profit Margin | -103.5% | -32.1% | -193.4% | -354.2% | -153.7% | -307.4% | -267.3% |
| Debt to Equity | 0.07x | 0.06x | 0.01x | 0.09x | 0.05x | 0.03x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
InnoPharmax Inc. dividends
InnoPharmax Inc. has not paid dividends in the last 7 fiscal years.
Who owns InnoPharmax Inc.
Ownership data of InnoPharmax Inc. is not available yet.
InnoPharmax Inc. company profile
- Company name
- InnoPharmax Inc.
- Ticker
- 4172.TWO
- ISIN
- TW0004172002
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 33
- Fiscal year end
- December
- Address
- No. 20 and No. 22, Lane 478, Taipei, Taiwan, 11492
- Phone
- 886 2 8797 7607
- Website
- innopharmax.com
About InnoPharmax Inc.
InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. The company offers Imipenem and Cilastatin sodium solution under the Bestnem brand for the treatment of infections caused by susceptible organisms, such as lower respiratory tract, skin and skin structure, intra-abdominal, gynecologic, bone, and joint infections; contrast agents, such as gadopentetate dimeglumine under the Gadomni brand; oncology agents comprising bendamustine under the Innomustine brand; immunological agents under the Immurin brand; and Inpheno tablets for rare diseases. It also provides active pharmaceutical ingredient, including orphan drug and MRI enhancing agents. In addition, the company's product pipeline comprises D07001, which is in initiated phase II trial for treatment of pancreatic and lung cancer, as well as in phase III clinical trial to treat biliary tract cancer; D0191801, which is in preclinical trial to treat diabetes; D0221901, which is in preclinical trial to treat type II diabetes; D0282102 for the treatment of lymphocytic leukemia/multiple myeloma/non-hodgkin's lymphoma; O0242001-1, O0242001-2, O0242001-3 which is in preclinical trial to treat MRI agent. Further, it provides MUCR system, OralPas, and OralPas Pro technology platform. The company was founded in 1994 and is based in Taipei, Taiwan.
InnoPharmax Inc. management
2- Weihua HaoManager
- Siru ChenAccounting Supervisor